Tebentafusp
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 178 publications
Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.
Journal: Human vaccines & immunotherapeutics
Published: May 21, 2026
ImmTAC: A Novel Platform of T-Cell Receptor-Based Soluble Bispecifics.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: May 10, 2026
Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 07, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 02, 2026
Current Therapies and Potential Strategies for Uveal Melanoma.
Journal: Drugs and drug candidates
Published: February 25, 2026
Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis.
Journal: Frontiers in oncology
Published: February 15, 2026
Escape From Synthetic T Cell Activator Tebentafusp by Genomic HLA Loss: A Case Report.
Journal: HLA
Published: February 01, 2026
Adverse Events and Toxicity of Systemic Treatments for Uveal Melanoma: A Systematic Review.
Journal: Cancers
Published: January 28, 2026
Dermatologic Adverse Events Associated with T-Cell Engager Therapy.
Journal: American journal of clinical dermatology
Published: January 26, 2026
Rectus Muscle Metastasis from Primary Uveal Melanoma: A Case Series and Literature Review.
Journal: Ocular oncology and pathology
Published: December 18, 2025
Last Updated: 06/30/2026